RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Sold by TD Asset Management Inc

TD Asset Management Inc trimmed its holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPTFree Report) by 23.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 117,618 shares of the company’s stock after selling 36,000 shares during the period. TD Asset Management Inc’s holdings in RAPT Therapeutics were worth $2,923,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in RAPT. Swiss National Bank boosted its stake in RAPT Therapeutics by 9.6% in the 3rd quarter. Swiss National Bank now owns 49,100 shares of the company’s stock worth $816,000 after buying an additional 4,300 shares during the last quarter. FMR LLC lifted its stake in shares of RAPT Therapeutics by 7.4% in the 3rd quarter. FMR LLC now owns 4,499,293 shares of the company’s stock valued at $74,778,000 after purchasing an additional 308,804 shares in the last quarter. Schonfeld Strategic Advisors LLC lifted its stake in shares of RAPT Therapeutics by 75.4% in the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 135,045 shares of the company’s stock valued at $2,244,000 after purchasing an additional 58,049 shares in the last quarter. Braidwell LP lifted its stake in shares of RAPT Therapeutics by 10.0% in the 3rd quarter. Braidwell LP now owns 1,082,512 shares of the company’s stock valued at $17,991,000 after purchasing an additional 98,112 shares in the last quarter. Finally, Euclidean Capital LLC lifted its stake in shares of RAPT Therapeutics by 15.2% in the 3rd quarter. Euclidean Capital LLC now owns 657,899 shares of the company’s stock valued at $10,934,000 after purchasing an additional 86,666 shares in the last quarter. 99.09% of the stock is owned by institutional investors and hedge funds.

RAPT Therapeutics Stock Performance

RAPT stock opened at $4.03 on Friday. RAPT Therapeutics, Inc. has a 52-week low of $3.86 and a 52-week high of $27.35. The stock’s 50 day moving average is $6.54 and its two-hundred day moving average is $13.99.

RAPT Therapeutics (NASDAQ:RAPTGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.01). As a group, equities research analysts predict that RAPT Therapeutics, Inc. will post -2.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

RAPT has been the topic of several research analyst reports. Leerink Partnrs lowered RAPT Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 21st. UBS Group lowered RAPT Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $61.00 to $10.00 in a research note on Thursday, February 22nd. Barclays downgraded RAPT Therapeutics from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $13.00 to $4.00 in a report on Friday, May 10th. Cantor Fitzgerald downgraded RAPT Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, February 20th. Finally, Guggenheim downgraded RAPT Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 10th. Nine analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $24.67.

View Our Latest Research Report on RAPT Therapeutics

About RAPT Therapeutics

(Free Report)

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

See Also

Want to see what other hedge funds are holding RAPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for RAPT Therapeutics, Inc. (NASDAQ:RAPTFree Report).

Institutional Ownership by Quarter for RAPT Therapeutics (NASDAQ:RAPT)

Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.